Trovafloxacin

Trovafloxacin

Clinical data
ATC code	J01MA13 (WHO)
Identifiers
IUPAC name 7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)- 1-(2,4-difluorophenyl)- 6-fluoro-4-oxo-[1,8] naphthyridine-3-carboxylic acid
CAS Number	147059-72-1
PubChem CID	62959
DrugBank	APRD01281
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H15F3N4O3
Molar mass	416.353 g/mol

WikiDoc Resources for Trovafloxacin
Articles
Most recent articles on Trovafloxacin Most cited articles on Trovafloxacin Review articles on Trovafloxacin Articles on Trovafloxacin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Trovafloxacin Images of Trovafloxacin Photos of Trovafloxacin Podcasts & MP3s on Trovafloxacin Videos on Trovafloxacin
Evidence Based Medicine
Cochrane Collaboration on Trovafloxacin Bandolier on Trovafloxacin TRIP on Trovafloxacin
Clinical Trials
Ongoing Trials on Trovafloxacin at Clinical Trials.gov Trial results on Trovafloxacin Clinical Trials on Trovafloxacin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Trovafloxacin NICE Guidance on Trovafloxacin NHS PRODIGY Guidance FDA on Trovafloxacin CDC on Trovafloxacin
Books
Books on Trovafloxacin
News
Trovafloxacin in the news Be alerted to news on Trovafloxacin News trends on Trovafloxacin
Commentary
Blogs on Trovafloxacin
Definitions
Definitions of Trovafloxacin
Patient Resources / Community
Patient resources on Trovafloxacin Discussion groups on Trovafloxacin Patient Handouts on Trovafloxacin Directions to Hospitals Treating Trovafloxacin Risk calculators and risk factors for Trovafloxacin
Healthcare Provider Resources
Symptoms of Trovafloxacin Causes & Risk Factors for Trovafloxacin Diagnostic studies for Trovafloxacin Treatment of Trovafloxacin
Continuing Medical Education (CME)
CME Programs on Trovafloxacin
International
Trovafloxacin en Espanol Trovafloxacin en Francais
Business
Trovafloxacin in the Marketplace Patents on Trovafloxacin
Experimental / Informatics
List of terms related to Trovafloxacin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Trovafloxacin (sold as Trovan® by Pfizer) is a broad spectrum antibiotic that inhibits the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV [2]. It was withdrawn from the market due to the risk of hepatotoxicity. It had better gram-positive bacterial coverage and less gram-negative coverage than the previous fluoroquinolones.

Controversy

In 1996, during a meningitis epidemic in Kano, Nigeria, the then-untested drug was administered to approximately 100 infected children. A panel of medical experts later implicated Pfizer in the incident, concluding the drug had been administered as part of an illegal clinical trial without authorization from the Nigerian government or consent from the children's parents. The case came to light in December 2000 as the result of an investigation by The Washington Post, and sparked significant public outcry. The Nigerian federal government has subsequently sued the drug giant for $8.5bn and Pfizer will face criminal and civil charges brought by the state and federal governments of Nigeria.

When it went on the market in 1998 Trovan became one of Pfizer's top-selling drugs. When first-quarter earnings were announced in April of that year, the company's earnings had increased by 15% over the previous year, with analysts attributing much of that increase to the sales of the "new antibiotic" Trovan. Pfizer had spent hundreds of millions of dollars developing Trovan. In the first year it brought over US$160 million and investors expected it to eventually bring in US$1 billion per year.

In June 1999 the U.S. Food and Drug Administration advised doctors to limit the prescription of Trovan after it had been found "strongly associated" with 14 cases of acute liver failure and six deaths. The FDA had received over 100 reports of liver problems in people taking Trovan, which was at that time being prescribed at a rate of 300,000 patients per month in the United States. Two days later the Committee for Proprietary Medicinal Products recommended to the European Commission that marketing approval of Trovan be suspended for a year. Between 2002 and 2005 the victims of the Trovan tests in Nigeria filed a series of unsuccessful lawsuits in the United States.